Key Highlights
- Coiled Therapeutics plc LSE:COIL fell 7.29% on 16 September 2026, according to the market snapshot.
- The company is a clinical-stage oncology Business developing AO-252, a brain-penetrant small-molecule TACC3 inhibitor.
- Earlier clinical data showed an 80% Clinical Benefit Rate in the twice-daily dosing cohort, compared with 40% in the once-daily cohort.
- Coiled is moving towards dose-expansion cohorts focused on ovarian and prostate cancer during 2026.
- A next-generation lipid-based softgel formulation of AO-252 has been developed to improve drug exposure and absorption.
- The first patient was dosed with the new formulation in August, with initial safety monitoring identifying no treatment-related adverse safety findings.
- The company raised £8.5 million gross in March 2026 to fund development of AO-252 through key clinical milestones in 2026 and 2027.
- The main investor focus is now shifting towards clinical data, dose expansion, formulation performance and the company's cash runway.
Why Is Coiled Therapeutics Stock in Focus on 16 September 2026?
Coiled Therapeutics plc LSE:COIL is in focus after its shares fell 7.29% on 16 September 2026, despite the company having several important clinical-development milestones ahead.
Coiled is developing AO-252, a first-in-class, brain-penetrant small-molecule inhibitor targeting TACC3. The company is positioning the drug as a potential precision-oncology treatment for difficult-to-treat solid tumours.
The Investment story changed significantly earlier this year when Coiled acquired the worldwide rights to AO-252 and completed an £8.5 million fundraising alongside its move to the AIM market. The company is now focused almost entirely on advancing the asset through clinical development.
For LSE:COIL, the share price is therefore highly sensitive to clinical progress, trial data, safety observations, formulation performance and financing expectations.
What Makes AO-252 Important for LSE:COIL?
AO-252 is designed to inhibit TACC3, a protein target associated with cancer-cell division and survival.
The company says TACC3 is frequently overexpressed in aggressive solid tumours while being less important in normal adult cells. AO-252 is designed to disrupt cancer-critical protein interactions, potentially creating a therapeutic mechanism for selected tumour types.
An additional feature is its ability to cross the blood-brain barrier, which could potentially make the drug relevant to cancers involving the brain or brain metastases.
However, AO-252 remains a clinical-stage asset. Early clinical observations are encouraging indicators but do not establish that the drug will ultimately demonstrate efficacy or receive regulatory approval.
What Did the Earlier Clinical Data Show?
The most important clinical update so far came in April 2026.
Coiled reported an 80% Clinical Benefit Rate among evaluable patients receiving the twice-daily regimen, compared with 40% in the once-daily cohort.
The company also reported tumour stabilisation or regression in 80% of evaluable patients in the twice-daily cohort, with some treatment durations exceeding six months.
These results supported the company's decision to move towards dose expansion.
The data remain early-stage, however, and the size and characteristics of the patient cohorts are important when assessing how much weight can be placed on the initial findings.
Why Is the New AO-252 Formulation Important?
Coiled has been working on a next-generation formulation of AO-252 to address limitations identified with the original tablet.
The company developed a lipid-based softgel formulation in which AO-252 is delivered in a pre-dissolved system. The objective is to achieve more consistent and dose-proportional absorption.
This matters because drug exposure can influence the ability to reach potentially therapeutic concentrations while maintaining an acceptable safety profile.
The first patient received the new formulation in the United States in August 2026. Initial post-dose monitoring identified no treatment-related adverse safety findings.
Investors will therefore be watching whether the new formulation improves pharmacokinetic performance and supports the next stage of clinical development.
Why Are Prostate and Ovarian Cancer Important for LSE:COIL?
Coiled has identified prostate and ovarian cancer as key indications for the planned dose-expansion programme.
The company is using the earlier clinical observations to focus development on indications where there may be a clearer opportunity to demonstrate clinical benefit.
The strategy is important because successful development of a clinical-stage oncology drug requires more than evidence of biological activity. The company needs to establish a meaningful dose, demonstrate efficacy across relevant patient populations and maintain an acceptable safety profile.
Consequently, data from the planned expansion cohorts could become major valuation events for LSE:COIL.
What Is the Financial Position of Coiled Therapeutics?
Coiled raised approximately £8.5 million gross in March 2026, with net proceeds of approximately £7.7 million after transaction costs.
The funds were raised specifically to support the development of AO-252 through key clinical milestones during 2026 and 2027.
For a clinical-stage biotechnology company, Cash Management is particularly important because research, clinical trials, Manufacturing and regulatory activities can consume substantial amounts of Capital before any commercial Revenue is generated.
Investors will therefore monitor the company's cash balance, clinical expenditure and the timing of future financing requirements alongside the clinical data.
What Are the Next Catalysts for LSE:COIL?
Several milestones could influence Coiled Therapeutics shares during the remainder of 2026.
The most important is progress with the planned dose-expansion cohorts in prostate and ovarian cancer.
Investors will also be watching data from patients receiving the new lipid-based AO-252 formulation, particularly pharmacokinetic and safety information.
Further clinical evidence could provide greater visibility on the drug's therapeutic potential.
Other areas to monitor include:
- Clinical trial recruitment.
- Dose-escalation and dose-expansion progress.
- Safety and tolerability data.
- Tumour response and disease-control measurements.
- Performance of the new AO-252 formulation.
- Cash utilisation.
- Potential pharmaceutical partnerships.
- Additional financing requirements.
What Is Driving the 7.29% Fall in LSE:COIL Today?
Coiled Therapeutics shares fell 7.29% on 16 September 2026.
There is no fresh negative clinical announcement identified on 16 September that definitively explains the entire daily decline. The company's most recent substantive development was the August dosing of the new AO-252 formulation, while its September corporate update related to the appointment of a joint corporate broker.
The decline therefore needs to be viewed in the context of LSE:COIL's clinical-stage profile and the market's sensitivity to upcoming trial milestones.
For a biotechnology company without an established commercial revenue stream, share-price movements can be particularly sensitive to changes in expectations around clinical data, financing and development timelines.
What Should Investors Watch Next for Coiled Therapeutics Stock?
The central issue for LSE:COIL is whether AO-252 can translate its early clinical signals into reproducible results during dose expansion.
The 80% Clinical Benefit Rate reported in the twice-daily cohort provides an important early data point, but future and larger datasets will be required to establish the consistency and significance of the findings.
The new formulation is another important component because improving drug exposure could potentially support the company's clinical-development strategy.
Investors should therefore focus on clinical evidence rather than the daily share-price movement, particularly as Coiled approaches additional prostate and ovarian cancer data during 2026.
What Is the Outlook for LSE:COIL After Today's Fall?
Coiled Therapeutics remains a clinical-stage oncology company with its valuation closely linked to the development prospects of AO-252.
The company has already secured funding for key 2026 and 2027 milestones, reported encouraging early clinical observations and introduced a new formulation designed to improve drug exposure.
The next phase is more data-intensive. Dose expansion, safety observations, pharmacokinetic results and tumour-response data will determine how the market assesses the programme's development potential.
The 7.29% decline on 16 September therefore comes ahead of several potentially important clinical milestones, rather than following a clearly identified negative clinical result.






Please wait processing your request...